Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Abstract Aims Lipoprotein (a)[Lp (a)] is a causal and independent risk factor for
cardiovascular disease (CVD). People with elevated Lp (a) are often prescribed statins as …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Abstract An Expert Panel convened by the National Lipid Association previously developed
a consensus set of recommendations for the patient-centered management of dyslipidemia …

2016 Chinese guidelines for the management of dyslipidemia in adults Page 1 Journal of
Geriatric Cardiology (2018) 15: 1-29 ©2018 JGC All rights reserved; www.jgc301.com http://www.jgc301.com; …

Abstract The National Lipid Association's Muscle Safety Expert Panel was charged with the
duty of examining the definitions for statin-associated muscle adverse events, development …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued
an evidence-based set of guidelines on cholesterol management in 2001. Since the …

Background Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density
lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of …

Background Efficacy and safety of alirocumab were compared with ezetimibe in
hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other …